Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇩🇰DK · Medicine#198500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
250 to 1.5K🎙 Weekly cadence·57 episodes·Last published 2w ago - Monthly Reach
Unique listeners across all episodes (30 days)
500 to 3K🇩🇰100% - Active Followers
Loyal subscribers who consistently listen
150 to 900
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 16 epsHost
Recent guests
No guests detected in recent episodes.
Recent episodes
Novel B-Cell Depleting Targeted Therapies to Improve Outcomes in Patients With Sjögren’s Disease
Jun 9, 2026
21m 09s
Improving Management of Difficult-to-Control Hypertension in Primary Care
Jun 1, 2026
40m 47s
Migliorare la gestione dell'ipertensione difficilmente controllabile nell'assistenza primaria
Jun 1, 2026
48m 12s
Verbesserung des Managements schwer einstellbarer Hypertonie in der Primärversorgung
Jun 1, 2026
30m 29s
Melhoria do manejo da hipertensão de difícil controle na Atenção Primária
Jun 1, 2026
52m 42s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/9/26 | Novel B-Cell Depleting Targeted Therapies to Improve Outcomes in Patients With Sjögren’s Disease✨ | B-Cell Depleting TherapiesSjögren’s Disease+3 | — | — | — | B-Cell DepletingSjögren’s Disease+3 | Novartis | 21m 09s | |
| 6/1/26 | Improving Management of Difficult-to-Control Hypertension in Primary Care✨ | hypertensionprimary care+3 | — | — | — | hypertensionprimary care+3 | AstraZeneca | 40m 47s | |
| 6/1/26 | Migliorare la gestione dell'ipertensione difficilmente controllabile nell'assistenza primaria✨ | gestione dell'ipertensioneassistenza primaria+1 | — | — | — | ipertensionegestione+3 | AstraZeneca | 48m 12s | |
| 6/1/26 | Verbesserung des Managements schwer einstellbarer Hypertonie in der Primärversorgung✨ | HypertoniePrimärversorgung+4 | — | — | — | HypertoniePrimärversorgung+3 | AstraZeneca | 30m 29s | |
| 6/1/26 | Melhoria do manejo da hipertensão de difícil controle na Atenção Primária✨ | hipertensãomanejo+3 | — | — | — | hipertensãocontrole+3 | AstraZeneca | 52m 42s | |
| 5/20/26 | Beyond Factor Xa: FXI/XIa Inhibition and the Next Era of Stroke Prevention in Atrial Fibrillation✨ | Stroke PreventionAtrial Fibrillation+4 | — | — | — | Stroke PreventionAtrial Fibrillation+3 | Bristol Myers Squibb | 1h 20m 06s | |
| 5/5/26 | プライマリ・ケアにおける難治性高血圧管理の改善✨ | 高血圧プライマリ・ケア+3 | — | — | — | 高血圧プライマリ・ケア+3 | アストラゼネカ | 36m 32s | |
| 5/5/26 | プライマリ・ケアにおける難治性高血圧管理の改善✨ | 高血圧プライマリ・ケア+3 | — | — | — | 高血圧プライマリ・ケア+3 | アストラゼネカ | — | |
| 5/5/26 | Mejora del manejo de la hipertensión de difícil control en Atención primaria✨ | hipertensiónAtención primaria+3 | — | — | — | hipertensiónAtención primaria+3 | AstraZeneca | 43m 12s | |
| 1/22/26 | Updating the Efficacy and Safety Experience of IL-17 Inhibitors✨ | EfficacySafety+3 | — | IL-17 Inhibitors | — | IL-17inhibitors+5 | UCB | 40m 00s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 12/11/25 | Late Breaking Clinical Trial Data from AHA 2025 on Approved and Emerging Lipid Lowering Therapies✨ | clinical trialslipid lowering therapies+3 | — | Lipid Lowering Therapies | — | clinical triallipid lowering+3 | Amgen | 54m 38s | |
| 12/11/25 | Update on Long-Acting Nebulized Bronchodilators for Guidance-Based Maintenance for Patients with COPD✨ | COPDlong-acting nebulized bronchodilators+3 | — | — | — | COPDbronchodilators+3 | Viatris Specialty LLC | 32m 56s | |
| 11/25/25 | Therapeutic Update on COPD with Type 2 Inflammation✨ | COPDType 2 Inflammation+3 | — | Therapeutic Update on COPD with Type 2 Inflammation | — | COPDType 2 Inflammation+5 | GSK | 26m 21s | |
| 11/24/25 | Updates on FcRn Blockers for Patients With Myasthenia Gravis: Personalized Treatment Strategies and Shared Decision Making✨ | FcRn BlockersMyasthenia Gravis+3 | — | — | — | FcRn BlockersMyasthenia Gravis+3 | argenx | 1h 03m 18s | |
| 11/17/25 | AANEM 2025: Conference Review and Analysis for New Data on Emerging BAFF/APRIL Inhibitors for the Management of Patients with Generalized Myasthenia Gravis✨ | conference reviewemerging therapies+4 | — | Generalized Myasthenia Gravis | — | AANEM 2025myasthenia gravis+4 | Vor Bio | 52m 08s | |
| 11/17/25 | ESC 2025: Conference Review and Analysis of Relevant Data Pertaining to LDL-C Lowering✨ | LDL-C loweringcardiovascular health+3 | — | — | — | LDL-CESC 2025+5 | Merck & Co., Inc. | 30m 24s | |
| 10/28/25 | Update on CD19-Targeted CAR T-cell Therapy to Treat Severe Refractory Systemic Lupus Erythematosus (SLE)✨ | CAR T-cell TherapySystemic Lupus Erythematosus+3 | — | — | — | CAR T-cell TherapySLE+3 | Bristol Myers Squibb | 1h 13m 27s | |
| 10/28/25 | Clinical Update on Non-Cystic Fibrosis Bronchiectasis: Strategies to Manage Exacerbations and Lung Function | This activity was supported by an educational grant from Insmed. Please go to https://academiccme.com/epcncfbepod/ and complete the evaluation to receive your CE/CME Credit. Credit is available through September 7, 2026. | — | ||||||
| 10/28/25 | Conference Review and Analysis of Relevant Data Pertaining to LDL-C | This activity was supported by an educational grant from Merck & Co., Inc. Please go to https://academiccme.com/front-matter/esc25-1/ and complete the evaluation to receive your CE/CME Credit. Credit is available through August 20, 2026. | — | ||||||
| 8/21/25 | Foundational Review of Standards of Care for At-Risk Patients with Dyslipidemia | This activity was supported by an educational grant from Merck & Co., Inc. Please go to https://academiccme.com/front-matter/esc25-1/ and complete the evaluation to receive your CE/CME Credit. Credit is available through August 20, 2026. | — | ||||||
| 7/31/25 | Review of McDonald Criteria 2024 Updates for the Management of Patients with Multiple Sclerosis | This activity was supported by an educational grant from EMD Serono. Please go to academiccme.com/McDonaldPod and complete the evaluation to receive your CE/CME Credit. Credit is available through October 23, 2025. | — | ||||||
| 7/18/25 | Implications of Obstructive Hypertrophic Cardiomyopathy (oHCM) for Heart Failure Specialists | This activity was supported by an educational grant from Bristol Myers Squibb. Please go to academiccme.com/HFPod and complete the evaluation to receive your CE/CME Credit. Credit is available through May 15, 2026. | — | ||||||
| 7/16/25 | ACC 2025 Conference Review and Analysis: Therapeutic Advances in Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) | This activity was supported by an educational grant from Alnylam Pharmaceuticals. Please go to http://academiccme.com/ATTRPod and complete the evaluation to receive your CE/CME Credit. Credit is available through June 25, 2026. | — | ||||||
| 3/17/25 | Clinical Update on Non-Cystic Fibrosis Bronchiectasis (NCFBE): Diagnostics, Pathophysiology, and Clinical Trial Analysis of Newer Therapies | This activity was supported by an educational grant from Insmed. Please go to academiccme.com/EPCNCFBE and complete the evaluation to receive your CE/CME Credit. Credit is available through September 19, 2025. | — | ||||||
| 3/17/25 | The Emerging Role of Activin Signaling Inhibitor Therapeutics to Improve Outcomes for Patients with PAH | This activity was supported by an educational grant from Merck & Co., Inc.. Please go to academiccme.com/EPCPAH and complete the evaluation to receive your CE/CME Credit. Credit is available through September 19, 2025. | — | ||||||
Showing 25 of 52
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.